Soares Karen sold $49K of CLOV

Soares Karen (Chief Legal Officer) sold 10,519 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jul 16, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

This is a disclosed open-market sale by an officer, not a corporate action or fundamental update. The presence of a pre-arranged 10b5-1 plan generally limits interpretive power.

02

Market read

Traders may note the insider sale, but the 10b5-1 designation suggests it is not a fresh discretionary signal.

03

What to watch

The filing does not indicate whether the sale was part of a broader planned schedule, nor does it provide any new operational or financial information about CLOV.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-16, transaction dated 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (DE).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CLOV disclosed an insider open-market sale by Chief Legal Officer Karen Soares of 10,519 shares at $4.67 on 2026-07-15.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely short-lived.

Evidence & confidence

The article provides only an insider transaction size and price, explicitly noting a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can coincide with periods of weaker sentiment or liquidity needs, so traders may still watch for follow-on selling.

Key entities

  • Clover Health Investments Corp. (DE)

    Subject of the Form 4 insider transaction disclosure.

  • Karen Soares

    Chief Legal Officer who sold 10,519 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.